spacer
home > ict > summer 2019 > choosing a winning model
PUBLICATIONS
International Clinical Trials

Choosing a Winning Model





How you approach implementing functional service provision (FSP) within your company has a direct effect on how successful those FSP teams will be. A ‘sustainable quality’ approach starts with picking the right model and navigating several areas of focus to ensure its success: planning, training, cultural fit, staff retention, technology, communication, agility, sponsor participation, performance indicators, expectations management, etc.

There are four basic models: uncapped time and materials (T&M), capped T&M, fixed fee, and ring-fenced/ full-time equivalents (FTEs) − each with pros and cons based on trial requirements and real-world experience.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author


Jo Marshall is the Director of FSP and UK Country Manager for CROS NT. Jo entered the industry as a clinical data manager for Searle and held global data management roles for Pharmacia and Pfizer before moving to a specialist biometrics consultancy and contributing to the growth of that company first as Associate Director, then Managing Director until its sale to CROS NT in 2013. Since being at CROS, she has supported a variety of initiatives including commercial, quality, efficiency, and product development, as well as operational department management for the statistical programming team. She holds an MSc in Clinical Data Management, is the treasurer for the Association for Clinical Data Management (ACDM), and chaired the ACDM conference organising committee for a number of years.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Qatar Airways Resumes Scheduled Belly-hold Cargo Operations to China in Response to Increased Demand

Qatar Airways becomes the first Middle Eastern carrier to resume belly-hold operations to all of its destinations in China by leveraging the flexibility and reliability of its modern fleet of 250 aircraft. Belly-hold cargo service to Beijing resumed on 30 March, services to Shanghai, Hangzhou and Chengdu will resume on 31 March and Guangzhou and Chongqing will resume on 01 April.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement